AU2011234453B2 - Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms - Google Patents
Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms Download PDFInfo
- Publication number
- AU2011234453B2 AU2011234453B2 AU2011234453A AU2011234453A AU2011234453B2 AU 2011234453 B2 AU2011234453 B2 AU 2011234453B2 AU 2011234453 A AU2011234453 A AU 2011234453A AU 2011234453 A AU2011234453 A AU 2011234453A AU 2011234453 B2 AU2011234453 B2 AU 2011234453B2
- Authority
- AU
- Australia
- Prior art keywords
- mirna
- expression
- antagonist
- aortic aneurysm
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 64
- 208000007474 aortic aneurysm Diseases 0.000 title claims abstract description 61
- 239000005557 antagonist Substances 0.000 title claims abstract description 52
- 230000002265 prevention Effects 0.000 title claims abstract description 13
- 239000002679 microRNA Substances 0.000 claims abstract description 63
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 36
- 108091070501 miRNA Proteins 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 108700000163 miRNA-29b Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 18
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- 230000000692 anti-sense effect Effects 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 210000001519 tissue Anatomy 0.000 claims description 12
- -1 COL1A3 Proteins 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 108060002895 fibrillin Proteins 0.000 claims description 8
- 102000013370 fibrillin Human genes 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 7
- 108010014258 Elastin Proteins 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 102100033167 Elastin Human genes 0.000 claims description 6
- 108010016731 PPAR gamma Proteins 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 102100031509 Fibrillin-1 Human genes 0.000 claims description 5
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 claims description 5
- 102000000536 PPAR gamma Human genes 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 206010060874 Aortic rupture Diseases 0.000 claims description 4
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 4
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 230000003828 downregulation Effects 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 238000003757 reverse transcription PCR Methods 0.000 claims description 4
- 238000000636 Northern blotting Methods 0.000 claims description 3
- 230000003313 weakening effect Effects 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 claims 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 description 38
- 210000000709 aorta Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 10
- 108091029162 miR-29 stem-loop Proteins 0.000 description 8
- 206010002329 Aneurysm Diseases 0.000 description 7
- 230000002792 vascular Effects 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 6
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960004586 rosiglitazone Drugs 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 101100328883 Arabidopsis thaliana COL1 gene Proteins 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 208000021654 bicuspid aortic valve disease Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 108091028606 miR-1 stem-loop Proteins 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 229960005095 pioglitazone Drugs 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 2
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091088477 miR-29a stem-loop Proteins 0.000 description 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 description 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 description 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000026799 smooth muscle cell apoptotic process Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010057453 Aortic dilatation Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 206010004552 Bicuspid aortic valve Diseases 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091092539 MiR-208 Proteins 0.000 description 1
- 108091068763 Mus musculus miR-127 stem-loop Proteins 0.000 description 1
- 108091067741 Mus musculus miR-129-1 stem-loop Proteins 0.000 description 1
- 108091066266 Mus musculus miR-129-2 stem-loop Proteins 0.000 description 1
- 108091068693 Mus musculus miR-136 stem-loop Proteins 0.000 description 1
- 108091068690 Mus musculus miR-140 stem-loop Proteins 0.000 description 1
- 108091068662 Mus musculus miR-154 stem-loop Proteins 0.000 description 1
- 108091067719 Mus musculus miR-182 stem-loop Proteins 0.000 description 1
- 108091067718 Mus musculus miR-183 stem-loop Proteins 0.000 description 1
- 108091067727 Mus musculus miR-186 stem-loop Proteins 0.000 description 1
- 108091065439 Mus musculus miR-223 stem-loop Proteins 0.000 description 1
- 108091066252 Mus musculus miR-31 stem-loop Proteins 0.000 description 1
- 108091066219 Mus musculus miR-322 stem-loop Proteins 0.000 description 1
- 108091066052 Mus musculus miR-329 stem-loop Proteins 0.000 description 1
- 108091066064 Mus musculus miR-337 stem-loop Proteins 0.000 description 1
- 108091067517 Mus musculus miR-377 stem-loop Proteins 0.000 description 1
- 108091067537 Mus musculus miR-379 stem-loop Proteins 0.000 description 1
- 108091033115 Mus musculus miR-411 stem-loop Proteins 0.000 description 1
- 108091032021 Mus musculus miR-434 stem-loop Proteins 0.000 description 1
- 108091028840 Mus musculus miR-758 stem-loop Proteins 0.000 description 1
- 108091066264 Mus musculus miR-98 stem-loop Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009791 fibrotic reaction Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000003843 furanosyl group Chemical group 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091007432 miR-29b Proteins 0.000 description 1
- 108091048549 miR-29b stem-loop Proteins 0.000 description 1
- 108091047189 miR-29c stem-loop Proteins 0.000 description 1
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10003675.5 | 2010-04-01 | ||
| EP10003675A EP2371370A1 (en) | 2010-04-01 | 2010-04-01 | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
| PCT/EP2011/055122 WO2011121120A1 (en) | 2010-04-01 | 2011-04-01 | ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2011234453A1 AU2011234453A1 (en) | 2012-10-18 |
| AU2011234453B2 true AU2011234453B2 (en) | 2015-01-22 |
Family
ID=42269707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011234453A Active AU2011234453B2 (en) | 2010-04-01 | 2011-04-01 | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9062307B2 (enExample) |
| EP (2) | EP2371370A1 (enExample) |
| JP (2) | JP6224455B2 (enExample) |
| CN (1) | CN102939090A (enExample) |
| AU (1) | AU2011234453B2 (enExample) |
| CA (1) | CA2795164C (enExample) |
| ES (1) | ES2690198T3 (enExample) |
| RU (1) | RU2012146518A (enExample) |
| WO (1) | WO2011121120A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US8618073B2 (en) | 2010-07-22 | 2013-12-31 | The University Of North Carolina At Chapel Hill | Use of miR-29 for cell protection |
| JP2015518475A (ja) * | 2012-04-10 | 2015-07-02 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 非アルコール性脂肪性肝炎の治療方法 |
| EP2861238A4 (en) | 2012-06-05 | 2016-03-16 | Capricor Inc | OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY |
| US9828603B2 (en) | 2012-08-13 | 2017-11-28 | Cedars Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| RU2712511C2 (ru) * | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
| US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| EP3247716A4 (en) | 2015-01-20 | 2018-10-17 | Miragen Therapeutics, Inc. | Mir-92 inhibitors and uses thereof |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2017214949A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种抑制 miRNA-29a 表达的慢病毒载体的构建及其应用 |
| WO2017219170A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 特异抑制人 miRNA-29a 和 miR-424 表达的慢病毒载体的构建及其应用 |
| WO2017219169A1 (zh) * | 2016-06-19 | 2017-12-28 | 毛侃琅 | 一种抑制 miRNA-29a 和 miR-185 表达的慢病毒载体及其应用 |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| US11759482B2 (en) | 2017-04-19 | 2023-09-19 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| CN109762883B (zh) * | 2019-01-31 | 2020-01-21 | 温州医科大学 | 血浆/血清外泌体hsa-miRNA-29-3p作为青光眼诊断标志物中的应用 |
| CN110511930B (zh) * | 2019-06-11 | 2023-01-10 | 河北医科大学 | Sal-miR-58及其在抑制血管炎性反应和动脉瘤形成中的用途 |
| CN117979975A (zh) * | 2021-05-07 | 2024-05-03 | 加利福尼亚大学董事会 | 用于预防和治疗动脉瘤、高血压、ards和其他与内皮功能障碍相关联的疾病的mirna抑制剂 |
| US20250304956A1 (en) * | 2021-08-06 | 2025-10-02 | Leadermed Champion Limited | miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
| CN114432453B (zh) * | 2022-02-25 | 2022-10-14 | 上海大学 | 敲低或抑制clec4d的试剂在制备心肌缺血再灌注损伤药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009018493A1 (en) * | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | A micro-rna family that modulates fibrosis and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| CL2008003699A1 (es) * | 2007-12-13 | 2009-10-09 | Takeda Pharmaceuticals Co | Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas. |
| CA2716343A1 (en) * | 2008-02-21 | 2009-08-27 | The Board Of Regents Of The University Of Texas System | Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof |
-
2010
- 2010-04-01 EP EP10003675A patent/EP2371370A1/en not_active Withdrawn
-
2011
- 2011-04-01 JP JP2013501865A patent/JP6224455B2/ja active Active
- 2011-04-01 AU AU2011234453A patent/AU2011234453B2/en active Active
- 2011-04-01 WO PCT/EP2011/055122 patent/WO2011121120A1/en not_active Ceased
- 2011-04-01 EP EP11711597.2A patent/EP2552454B1/en active Active
- 2011-04-01 RU RU2012146518/15A patent/RU2012146518A/ru not_active Application Discontinuation
- 2011-04-01 CN CN2011800172888A patent/CN102939090A/zh active Pending
- 2011-04-01 CA CA2795164A patent/CA2795164C/en active Active
- 2011-04-01 US US13/637,924 patent/US9062307B2/en active Active
- 2011-04-01 ES ES11711597.2T patent/ES2690198T3/es active Active
-
2016
- 2016-03-24 JP JP2016060073A patent/JP2016193888A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009018493A1 (en) * | 2007-07-31 | 2009-02-05 | The Board Of Regents Of The University Of Texas System | A micro-rna family that modulates fibrosis and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| US9062307B2 (en) | 2015-06-23 |
| CN102939090A (zh) | 2013-02-20 |
| EP2552454A1 (en) | 2013-02-06 |
| US20130116303A1 (en) | 2013-05-09 |
| ES2690198T3 (es) | 2018-11-19 |
| CA2795164A1 (en) | 2011-10-06 |
| JP6224455B2 (ja) | 2017-11-01 |
| EP2371370A1 (en) | 2011-10-05 |
| RU2012146518A (ru) | 2014-05-10 |
| JP2016193888A (ja) | 2016-11-17 |
| CA2795164C (en) | 2019-06-18 |
| EP2552454B1 (en) | 2018-07-11 |
| AU2011234453A1 (en) | 2012-10-18 |
| WO2011121120A1 (en) | 2011-10-06 |
| JP2013523696A (ja) | 2013-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011234453B2 (en) | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms | |
| US7994150B2 (en) | Micro-RNAs that modulate smooth muscle proliferation and differentiation and uses thereof | |
| Piccoli et al. | Non-coding RNAs as modulators of the cardiac fibroblast phenotype | |
| KR20100061798A (ko) | 섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도 | |
| WO2010103015A1 (en) | Microrna for diagnostic and therapeutic purposes in cardiovascular diseases | |
| KR102246814B1 (ko) | 치료용 올리고뉴클레오타이드 | |
| HK1219753A1 (zh) | 包含包封的antagomir的组合物 | |
| Hu et al. | MicroRNA-1 downregulation induced by carvedilol protects cardiomyocytes against apoptosis by targeting heat shock protein 60 | |
| Guedes et al. | High fat diet reduces the expression of miRNA‐29b in heart and increases susceptibility of myocardium to ischemia/reperfusion injury | |
| EP3329004A1 (en) | Therapeutic oligonucleotides | |
| CN102266569B (zh) | miR-199a及其抑制剂的应用 | |
| Latsios et al. | MicroRNAs in the diagnosis and treatment of unstable angina | |
| WO2013068600A1 (en) | Medicament for the treatment of cardiac disease | |
| US20200095583A1 (en) | Methods and Compositions for Managing Vascular Conditions | |
| Preethi et al. | Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications | |
| EP3058070A2 (en) | Vascular re-modelling | |
| KR20150078074A (ko) | microRNA-365 활성화제를 포함하는 혈관평활근세포 증식 또는 이동 억제용 약학적 조성물 | |
| EP3737763A1 (en) | Pharmaceutical composition for preventing or treating muscular disease or cachexia comprising, as active ingredient, mirna located in dlk1 -dio3 cluster or variant thereof | |
| CN102639560A (zh) | 靶向Sipa1l1的siRNA用于降低脂肪生成的用途 | |
| WO2018024878A1 (en) | Methods and compositions for reducing pcsk9 expression | |
| Wang et al. | CircHelz inhibition protects against angiotensin II-induced cardiac fibrosis via miR-29b modulation | |
| WO2024165603A1 (en) | Pharmaceutical composition for use in treatment of venous thromboembolism | |
| KR20160038190A (ko) | 마이크로rna-192에 대한 길항제를 포함하는 간 섬유화 억제용 조성물 | |
| CN102459594A (zh) | Zdhhc2活性抑制剂在调节脂肪生成中的用途 | |
| Tang | Novel mechanisms regulating vascular smooth muscle proliferation and differentiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |